Review of Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies

Pre-publication Review of

Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies

Reviewed On January 02, 2022

Verified

Submitted to

Reviewed by

Actions

Reviewed on January 02, 2022

Source

References

O., R. O., Hamza, J., Abdullah, W., S., A. S., M., A. H., Iuliana, D., Ashgan, A., F., A. A., T., A. A., M., B. S., S., B. A., H., Q. M., M., A. A., M., H. A. 2022. Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies. Vaccines.